Table 4.
Incidence of Adverse Effects, Sedation Score, and Apgar Score in Studied Groups
| Parameter | Group C n = 30 |
Group N n = 30 |
Group M n = 30 |
X2 | P | |
|---|---|---|---|---|---|---|
| Hypotension | 5 (16.66%) | 3 (10%) | 5 (16.66%) | 0.719 | 0.69 | |
| Vomiting | 4 (13.33%) | 3 (10%) | 1 (3.33%) | 1.92 | 0.38 | |
| Nausea | 2 (6.66%) | 1 (3.33%) | 0 (0%) | 2.07 | 0.35 | |
| Shivering | 3 (10%) | 1 (3.33%) | 0 (0%) | 3.66 | 0.16 | |
| Sedation score | 0.61±0.32 | 1.78±0.76 | 2.75±0.54 | (F) 106.36 | <0.001 | |
| Apgar Score | (1) min | 7.7±0.84 | 7.1±0.91 | 6.9±0.73 | (F) 7.54 | <0.001 |
| (5) min | 9.4±1.7 | 9.2±1.8 | 8.7±0.43 | (F) 1.85 | 0.16 | |
Notes: Data were expressed as No (%), mean±SD; group C, control group; group N, nalbuphine group; group M, midazolam group; F-test (ANOVA), one way analysis of variance; X2, chi-squared test; p < 0.05 was significant and p <0.001 was highly significant.